The U.S. Department of Justice’s Antitrust Division has filed proposed Final Judgments in two separate civil antitrust cases involving major healthcare-related companies.

In the first case, filed in the U.S. District Court for the Southern District of Ohio, the government alleges that OhioHealth Corporation engaged in anticompetitive conduct through contract provisions with payors that violate Section 1 of the Sherman Act. According to the complaint, OhioHealth included terms in its agreements that prevented or discouraged insurers from offering more affordable health insurance plans. The proposed Final Judgment would require OhioHealth to remove such provisions from its contracts and prohibits the company from including similar terms in future agreements. The Antitrust Division has made the case filings publicly available on its website, inviting public comments for 60 days.

The second case, filed in the U.S. District Court for the District of Columbia, involves Edwards LifeSciences Corp. and Genesis Medtech Group Limited. The government alleges that Edwards’ acquisition of JC Medical, Inc., a transaction with Genesis, violated the Hart-Scott-Rodino (HSR) Act’s requirements for premerger notification. As part of the proposed settlement, Edwards must pay a $10 million civil penalty, adopt an antitrust compliance program, and notify the Federal Trade Commission before any future acquisitions involving companies marketing or conducting clinical trials in the United States related to a particular heart valve replacement device. Genesis is also required to pay a $2 million civil penalty. Like the first case, all complaint documents are available online and public comments will be accepted for 60 days.

Submission information for comments and access to court filings has been provided by the Justice Department alongside the announcement. The cases underscore the department’s continued focus on addressing anticompetitive practices and merger compliance in the healthcare sector.